Kera Capital Partners Inc. acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 23,052 shares of the financial services provider’s stock, valued at approximately $3,975,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter valued at $201,000. AQR Capital Management LLC bought a new position in shares of iShares Biotechnology ETF in the 1st quarter worth $455,000. Millennium Management LLC boosted its position in shares of iShares Biotechnology ETF by 140.8% in the 1st quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock worth $5,330,000 after purchasing an additional 143,893 shares during the last quarter. M&T Bank Corp grew its stake in shares of iShares Biotechnology ETF by 39.3% during the second quarter. M&T Bank Corp now owns 2,660 shares of the financial services provider’s stock worth $337,000 after purchasing an additional 750 shares during the period. Finally, Walleye Capital LLC grew its stake in shares of iShares Biotechnology ETF by 26.8% during the second quarter. Walleye Capital LLC now owns 4,655 shares of the financial services provider’s stock worth $589,000 after purchasing an additional 985 shares during the period. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Trading Up 0.1%
NASDAQ IBB opened at $173.64 on Friday. iShares Biotechnology ETF has a 12 month low of $123.61 and a 12 month high of $179.64. The stock has a 50-day simple moving average of $170.57 and a 200 day simple moving average of $170.64.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
